1. Kaur, S., Kumar, S., Momi, N., Sasson, A.R. & Batra, S.K. Mucins in pancreatic cancer and its microenvironment. Nature reviews. Gastroenterology & hepatology10, 607-620 (2013).
2. Kufe, D.W. Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer9, 874-885 (2009).
3. Hollingsworth, M.A. & Swanson, B.J. Mucins in cancer: protection and control of the cell surface. Nature Reviews Cancer4, 45-60 (2004).
4. Aithal, A. et al. MUC16 as a novel target for cancer therapy. Expert Opinion on Therapeutic Targets22, 675-686 (2018).
5. Chaturvedi, P., Singh, A.P. & Batra, S.K. Structure, evolution, and biology of the MUC4 mucin. The FASEB Journal22, 966-981 (2008).
6. Moniaux, N. et al. Alternative splicing generates a family of putative secreted and membrane‐associated MUC4 mucins. European journal of biochemistry267, 4536-4544 (2000).
7. Moniaux, N. et al. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. J Biochemical Journal338, 325-333 (1999).
8. Bafna, S. et al. MUC4, a Multifunctional Transmembrane Glycoprotein, Induces Oncogenic Transformation of NIH3T3 Mouse Fibroblast Cells. Cancer Research68, 9231-9238 (2008).
9. Carraway, K.L., Theodoropoulos, G., Kozloski, G.A. & Carothers Carraway, C.A. Muc4/MUC4 functions and regulation in cancer. Future Oncol5, 1631-1640 (2009).
10. Chakraborty, S., Jain, M., Sasson, A.R. & Batra, S.K. MUC4 as a diagnostic marker in cancer. Expert Opinion on Medical Diagnostics2, 891-910 (2008).
11. Gautam, S.K. et al. MUC4 mucin-a therapeutic target for pancreatic ductal adenocarcinoma. Expert opinion on therapeutic targets21, 657-669 (2017).
12. Gautam, S.K. et al. in Seminars in Immunology 101391 (Elsevier, 2020).
13. Singh, A.P., Chaturvedi, P. & Batra, S.K. Emerging Roles of MUC4 in Cancer: A Novel Target for Diagnosis and Therapy. Cancer Research67, 433-436 (2007).
14. Kumar, S. et al. Genetic variants of mucins: unexplored conundrum. Carcinogenesis38, 671-679 (2017).
15. Albrecht, H. & Carraway, K.L. MUC1 and MUC4: Switching the Emphasis from Large to Small. Cancer Biotherapy & Radiopharmaceuticals26, 261-271 (2011).
16. Chaturvedi, P. et al. MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells. Cancer research68, 2065-2070 (2008).
17. Jonckheere, N. et al. The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways. PLoS ONE7, e32232 (2012).
18. Lakshmanan, I. et al. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget6, 21085-21099 (2015).
19. Liberelle, M. et al. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis. Scientific Reports9, 16678 (2019).
20. Ponnusamy, M.P. et al. MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. British Journal of Cancer99, 520-526 (2008).
21. Moniaux, N. et al. Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. British journal of cancer97, 345-357 (2007).
22. Banerjee, K. et al. Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells. Genes & Cancer10, 52-62 (2019).
23. Liu, L. et al. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. Journal of Biomedical Materials Research Part A, 1-10 (2020).
24. Aithal, A. et al. in PANCREAS, Vol. 48 1401-1402 (Lippincott Williams & Two Commerce SQ, 2001 Market St, Philadelphia., 2019).
25. C. Orzechowski, A.A., W. Junker, P. Kshirsagar, S. Batra, M. Jain. Generation and characterization of novel antibodies against the β subunit of MUC4. Cancer Research 78 (13 Supplement), 3829-3829. (
26. Boynton, Z.L. et al. Reduction of Cell Lysate Viscosity during Processing of Poly(3-Hydroxyalkanoates) by Chromosomal Integration of the Staphylococcal Nuclease Gene in Pseudomonas putida. Applied and Environmental Microbiology65, 1524-1529 (1999).
27. Rodríguez Gamero, J.E. et al. Nuclease expression in efficient polyhydroxyalkanoates-producing bacteria could yield cost reduction during downstream processing. Bioresource Technology261, 176-181 (2018).
28. Manavalan, P. & Johnson, W.C. Sensitivity of circular dichroism to protein tertiary structure class. Nature305, 831-832 (1983).
29. Abdul-Gader, A., Miles, A.J. & Wallace, B.A. A reference dataset for the analyses of membrane protein secondary structures and transmembrane residues using circular dichroism spectroscopy. Bioinformatics27, 1630-1636 (2011).
30. Whitmore, L. & Wallace, B.A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Research32, W668-W673 (2004).
31. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols5, 725-738 (2010).
32. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nature Methods12, 7-8 (2015).
33. Yang, J. & Zhang, Y. I-TASSER server: new development for protein structure and function predictions. Nucleic acids research43, W174-W181 (2015).
34. Senapati, S., Das, S. & Batra, S.K. Mucin-interacting proteins: from function to therapeutics. Trends in biochemical sciences35, 236-245 (2010).
35. Bafna, S., Kaur, S. & Batra, S.K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene29, 2893-2904 (2010).
36. Bhatia, R. et al. Cancer-associated mucins: role in immune modulation and metastasis. Cancer metastasis reviews38, 223-236 (2019).
37. Chaturvedi, P. et al. MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins. Molecular Cancer Research5, 309 (2007).
38. Mukhopadhyay, P. et al. MUC4 Overexpression Augments Cell Migration and Metastasis through EGFR Family Proteins in Triple Negative Breast Cancer Cells. PLoS ONE8, 1-14 (2013).
39. Jain, M. et al. Monoclonal Antibodies Recognizing the Non-Tandem Repeat Regions of the Human Mucin MUC4 in Pancreatic Cancer. PLoS ONE6, e23344 (2011).
40. Tegel, H., Tourle, S., Ottosson, J. & Persson, A. Increased levels of recombinant human proteins with the Escherichia coli strain Rosetta(DE3). Protein Expression and Purification69, 159-167 (2010).
41. Kim, S. & Lee, S.B. Rare codon clusters at 5′-end influence heterologous expression of archaeal gene in Escherichia coli. Protein Expression and Purification50, 49-57 (2006).
42. Kleber-Janke, T. & Becker, W.-M. Use of Modified BL21(DE3) Escherichia coli Cells for High-Level Expression of Recombinant Peanut Allergens Affected by Poor Codon Usage. Protein Expression and Purification19, 419-424 (2000).
43. Snyder, R.O. & Flotte, T.R. Production of clinical-grade recombinant adeno-associated virus vectors. Current Opinion in Biotechnology13, 418-423 (2002).
44. Kalipatnapu, S. & Chattopadhyay, A. Membrane protein solubilization: recent advances and challenges in solubilization of serotonin1A receptors. IUBMB Life57, 505-512 (2005).
45. Sreerama, N. & Woody, R.W. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Analytical biochemistry287, 252-260 (2000).
46. Micsonai, A. et al. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. Proceedings of the National Academy of Sciences of the United States of America112, E3095-3103 (2015).
47. Sreerama, N. & Woody, R.W. Structural composition of betaI- and betaII-proteins. Protein Sci12, 384-388 (2003).
48. Manavalan, P. & Johnson, W.C., Jr. Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra. Analytical biochemistry167, 76-85 (1987).
49. Lise, S. & Jones, D.T. Sequence patterns associated with disordered regions in proteins. Proteins58, 144-150 (2005).
50. Uversky, V.N. What does it mean to be natively unfolded? European journal of biochemistry269, 2-12 (2002).
51. Carmicheal, J. et al. Presence and structure-activity relationship of intrinsically disordered regions across mucins. The FASEB Journal34, 1939-1957 (2020).
52. Bhatia, R. et al. MUC4 interacts and stabilize EGFR1 in a ligand‐dependent manner leading to sustained oncogenic signaling. The FASEB Journal33, 631.633-631.633 (2019).
53. Kloczkowski, A., Ting, K.-L., Jernigan, R.L. & Garnier, J. Combining the GOR V algorithm with evolutionary information for protein secondary structure prediction from amino acid sequence. 49, 154-166 (2002).
54. Wu, S. & Zhang, Y. LOMETS: A local meta-threading-server for protein structure prediction. Nucleic Acids Research35, 3375-3382 (2007).
55. Senapati, S. et al. Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. J Clinical cancer research17, 267-274 (2011).
56. Arpin, M., Chirivino, D., Naba, A. & Zwaenepoel, I. Emerging role for ERM proteins in cell adhesion and migration. Cell Adhesion & Migration5, 199-206 (2011).
57. Clucas, J. & Valderrama, F. ERM proteins in cancer progression. Journal of Cell Science127, 267 (2014).
58. Meng, Y. et al. Ezrin promotes invasion and metastasis of pancreatic cancer cells. Journal of Translational Medicine8, 61 (2010).
59. Blalock, T.D. et al. Functions of MUC16 in corneal epithelial cells. Investigative ophthalmology visual science48, 4509-4518 (2007).
60. Koopaei, N.N. et al. Optimization of rPDT fusion protein expression by Escherichia coli in pilot scale fermentation: a statistical experimental design approach. AMB Express8, 135 (2018).
61. Aithal, A. et al. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer. PLoS ONE13, e0193907 (2018).
62. Ye, G. et al. Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system. Gene therapy18, 135 (2011).